Astrazeneca

FromAstraZeneca ([email protected])
Subject (124)Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer
Preheader (124)Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer
Typography
Arial
Colors
Text Analysis
Body Words221
Subject Words17
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px754 px
X-Spam Score-0.2
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeAfternoon

Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer

Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer